Toggle Main Menu Toggle Search

Open Access padlockePrints

Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants

Lookup NU author(s): Muhammed Gok, John Asher, Marsha Nicholson, David Talbot


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Background: Kidneys from non-heart-beating donors (NHBDs) have high rates of delayed graft function (DGF). Use of calcineurin inhibitors is associated with a reduction in renal blood flow, which may delay graft recovery from ischaemic acute tubular necrosis. Methods: To assess whether daclizumab (DZB) could safely replace tacrolimus in the immediate postoperative period, patients were randomized to receive DZB induction and daily mycophenolate mofetil with steroids (DZB group) or standard tacrolimus-based triple therapy (control group). Tacrolimus was given to patients in the DZB group when the serum creatinine level dropped below 350 mu mol/l. Results: Fifty-one patients were recruited at two centres over a 2-year interval between 2000 and 2003. The overall rate of immediate function was 28 per cent (13 of 46 grafts), with the highest rate in recipients of machine-perfused kidneys treated with DZB (eight of 15 patients). Conclusion: Induction with DZB and delayed introduction of tacrolimus reduced the incidence of DGF in recipients of machine-perfused NHBD kidneys.

Publication metadata

Author(s): Wilson CH, Brook NR, Gok MA, Asher JF, Nicholson ML, Talbot D

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: British Journal of Surgery: Annual Meeting of the Association of Surgeons of Great Britian and Ireland

Year of Conference: 2005

Pages: 681-687

ISSN: 0007-1323

Publisher: John Wiley & Sons Ltd.


DOI: 10.1002/bjs.4976

Library holdings: Search Newcastle University Library for this item

ISBN: 13652168